AKT1 and prostate carcinoma: KEGG mainly concerns pathways in cancer, proteoglycans in cancer, EGFR tyrosine kinase inhibitor resistance, calcium signaling pathway, Rap1 signaling pathway, AGE-RAGE signaling pathway in diabetic complications, PI3K-Akt signaling pathway, prostate cancer, lipid and atherosclerosis, and chemical carcinogenesis–receptor activation.